



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 8, 2011

Michael G. McGuinness
Chief Operating Officer, Chief Financial Officer and Secretary
Manhattan Pharmaceuticals, Inc.
48 Wall Street
New York, New York 10005

Re: Manhattan Pharmaceuticals, Inc.
Schedule 14A
Filed March 1, 2011
File No. 001-32639

Dear Mr. McGuinness:

We have limited our review of the above proxy statement to the issue identified below.

Please respond to this letter within ten business days by amending your filing or by advising us when you will provide the requested response. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your filing, we may have additional comments.

1. Please amend your filing to include disclosure that clearly states the number of shares of common stock that may be issued in connection with the "Nordic Settlement" on a pre and post split basis.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable Exchange Act rules require. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

In responding to our comments, please provide a written statement from the company acknowledging that:

- the company is responsible for the adequacy and accuracy of the disclosure in the filing;
- staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and

Michael G. McGuinness
Manhattan Pharmaceuticals, Inc.
March 8, 2011
Page 2

- the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

You may contact Johnny Gharib at (202) 551-3170 or me at (202) 551-3715 with any questions.

Sincerely,

Jeffrey Riedler
Assistant Director